Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences Retained by Siena Biotech for Biomarker Services

NEW YORK (GenomeWeb News) – Siena Biotech has retained Proteome Sciences under a Master Research Agreement to supply protein and peptide biomarkers services for its drug discovery programs, Proteome announced today.

The UK-based proteomics firm added that as the first project under the agreement it will apply its PS Biomarkers services to analyze post-translational modifications on a neurological disease-related protein. Using its sample preparation and analytical methods in combination with Thermo Fisher Scientific's Orbitrap Velos mass spectrometry, Proteome will "deliver a high-density PTM map of Siena Biotech's protein target."

Such maps can confirm proof of disease mechanism and/or mode of action of targeted therapeutics to help a drug firm decide whether to proceed with further development, Proteome said.

Financial and other terms of the deal were not disclosed.

Siena Biotech is a clinical-stage drug development firm based in Italy.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.